1. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial;Ader;Lancet Infect. Dis.,2021
2. C1 esterase inhibition: targeting multiple systems in COVID-19;Adesanya;J. Clin. Immunol.,2021
3. Favipiravir: a new and emerging antiviral option in COVID-19;Agrawal;Med. J. Armed Forces India,2020
4. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: case series of four critically ill patients treated with leronlimab;Agresti;J. Transl. Autoimmun.,2021
5. Small-molecule antiviral agents in ongoing clinical trials for COVID-19;Apaydın;Curr. Drug Targets,2021